Brad Newhouse

USPTO Granted Patents = 18 (Patent Applications = 5)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 13)

Average Co-Inventor Count = 10.9

ph-index = 5

Forward Citations = 54(Granted Patents)

Location History:

Broomfield, CO (US) (2009)
Boulder, CA (US) (2017)
Boulder, CO (US) (2012 - 2024)

Company Filing History:

Ventirx Pharmaceuticals, Inc.

patents

4. 3 out of 38

Mirati Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11964989 - KRas G12D inhibitors (2024-04-23),

2. 11453683 - KRas G12D inhibitors (2022-09-27),

3. 11247990 - Bicyclic fused pyridine compounds as inhibitors of TAM kinases (2022-02-15),

4. 10669269 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2020-06-02),

5. 10647715 - KRas G12C inhibitors (2020-05-12),

6. 10154995 - Serine/threonine kinase inhibitors (2018-12-18),

7. 9969694 - N-(arylalkyl)-N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors (2018-05-15),

8. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2017-11-07),

9. 9763942 - Serine/threonine kinase inhibitors (2017-09-19),

10. 9670208 - Serine/threonine kinase inhibitors (2017-06-06),

11. 9655904 - Substituted benzoazepines as toll-like receptor modulators (2017-05-23),

12. 9174981 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2015-11-03),

13. 9126940 - Substituted benzoazepines as toll-like receptor modulators (2015-09-08),

14. 8691809 - Substituted benzoazepines as toll-like receptor modulators (2014-04-08),

15. 8394795 - Pyrazole [3, 4-B] pyridine Raf inhibitors (2013-03-12),

Title: Unveiling the Innovative Mind of Brad Newhouse

Introduction:

Brad Newhouse, a prolific inventor hailing from Boulder, CO (US), has made significant strides in the field of pharmaceutical innovations. With a remarkable portfolio of 18 patents to his name, Brad is a trailblazer in developing compounds that inhibit the activity of KRas G12D, particularly in the treatment of cancer.

Latest Patents:

Among his latest patents are the KRas G12D inhibitors – compounds designed to effectively combat the activity of KRas G12D. These compounds, characterized by a distinct structure represented by Formula (I) or its pharmaceutically acceptable salt, hold immense promise in the realm of cancer treatment.

Career Highlights:

Brad Newhouse's exemplary career has been intertwined with esteemed companies such as Array Biopharma Inc. and Genentech, Inc., where his groundbreaking research has left an indelible mark. His innovative approach to pharmaceutical compositions and methods of treatment underscores his commitment to advancing healthcare solutions.

Collaborations:

Throughout his career, Brad has collaborated with esteemed professionals such as James F Blake and Joseph P Lyssikatos. Together, they have synergized their expertise to drive forward cutting-edge research and development in the field of oncology and drug discovery.

Conclusion:

In conclusion, Brad Newhouse stands as a beacon of innovation in the world of pharmaceuticals. His relentless pursuit of novel compounds and treatment modalities signifies a commitment to revolutionizing cancer care. With a stellar track record and a visionary approach, Brad continues to inspire future generations of inventors and researchers in the quest for transformative healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.